XML 44 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Oct. 31, 2012
Oct. 31, 2011
Oct. 31, 2012
Oct. 31, 2011
Operating revenue:        
Personalized oncology solutions $ 459 $ 590 $ 1,377 $ 1,188
Translational oncology solutions 999 1,151 2,187 2,184
Total operating revenue 1,458 1,741 3,564 3,372
Costs and operating expenses:        
Cost of personalized oncology solutions 582 461 1,354 945
Cost of translational oncology solutions 475 620 1,174 1,104
Research and development 436 1,008 823 1,616
Sales and marketing 680 651 1,389 1,262
General and administrative 1,201 1,470 2,340 3,130
Total costs and operating expenses 3,374 4,210 7,080 8,057
Loss from operations (1,916) (2,469) (3,516) (4,685)
Other income:        
Change in fair value of warrant liability (52) 110 233 288
Other (expense) income (5) 10 (10) 10
Total other (expense) income (57) 120 223 298
Loss before provision for income taxes (1,973) (2,349) (3,293) (4,387)
Provision for income taxes 1 0 4 0
Net loss $ (1,974) $ (2,349) $ (3,297) $ (4,387)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) $ (0.04) $ (0.05) $ (0.07) $ (0.09)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) 47,079,000 46,790,000 47,073,000 46,606,000